Clinical Scorecard: Optegra Expands Light Therapy for Dry AMD Across UK Clinics
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry age-related macular degeneration (AMD) |
| Key Mechanisms | Eye-light uses photobiomodulation (PBM), delivering yellow light at approximately 590 nm and red light at approximately 630 nm through closed eyelids, with the aim of supporting retinal cell function and slowing structural changes associated with dry AMD. |
| Target Population | People aged 50 years and over with a confirmed diagnosis of dry AMD who are assessed as suitable for treatment. |
| Care Setting | Treatment is offered at Optegra hospitals in London, Manchester, Colchester, Bradford and Hampshire; patients may be referred by an optometrist or self-refer. |
Key Highlights
- Optegra is expanding access to Espansione’s eye-light PBM treatment across five UK hospital locations.
- Sessions treat both eyes simultaneously and last around 12 minutes; the stated protocol is eight sessions over four weeks.
- Some patients may receive a further six-session cycle approximately four to six months later.
- The article reports study findings of at least five-letter visual acuity gains in more than 20% of treated patients after four months and a statistically significant reduction in mean drusen volume versus sham treatment.
- The article states that further research is needed to establish the durability of effects and identify which patients are most likely to benefit.
Guideline-Based Recommendations
Diagnosis
- Treatment is available to patients aged 50 years and over with a confirmed diagnosis of dry AMD, following assessment for suitability.
Management
- The article describes traditional dry AMD management as monitoring, lifestyle modification, smoking cessation and nutritional advice.
- Eye-light treatment is non-invasive and does not require injections, surgery or postoperative recovery.
Monitoring & Follow-up
- The article identifies monitoring as part of traditional dry AMD management.
- It does not specify a monitoring schedule for patients receiving eye-light treatment.
Risks
- The article does not report specific adverse effects or contraindications for eye-light treatment.
- The durability of reported effects and the patient groups most likely to benefit remain to be established.
Patient & Prescribing Data
Patients aged 50 years and over with confirmed dry AMD who are assessed as suitable; referral by an optometrist or direct self-referral is accepted.
The Optegra protocol comprises eight sessions over four weeks, with a possible additional six-session cycle approximately four to six months later. Each session lasts around 12 minutes and treats both eyes simultaneously using a mask over closed eyelids.
Clinical Best Practices
- Confirm dry AMD diagnosis and assess patient suitability before treatment.
- Explain that the article reports study findings of visual acuity and drusen-volume changes, while noting that further research is needed on durability and patient selection.
- Continue to recognize monitoring, lifestyle modification, smoking cessation and nutritional advice as management approaches described in the article.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
